We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · September 24, 2019

Third-Line and Beyond Rovalpituzumab Tesirinen in DLL3-Expressing, Relapsed/ Refractory Small-Cell Lung Cancer

Clinical Cancer Research

 

Additional Info

Clinical Cancer Research
Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients With DLL3-Expressing, Relapsed/ Refractory Small Cell Lung Cancer: Results From the Phase II TRINITY Study
Clin. Cancer Res 2019 Sep 10;[EPub Ahead of Print], D Morgensztern, B Besse, L Greillier, R Santana-Davila, N Ready, CL Hann, BS Glisson, AF Farago, A Dowlati, CM Rudin, S Le Moulec, S Lally, S Yalamanchili, J Wolf, R Govindan, DP Carbone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading